ID Labs R3t@trutide 32mg/Pen is a pre-filled research peptide developed for laboratory and scientific investigation into metabolic regulation. R3t@trutide is an investigational triple receptor agonist that simultaneously targets the GLP-1, GIP, and glucagon receptors, making it one of the most extensively studied next-generation metabolic peptides currently in clinical development.

The convenient pre-filled pen format provides a ready-to-use research presentation, making it suitable for laboratory environments where consistency and handling efficiency are important.

Research Overview

R3t@trutide (LY3437943) is an investigational peptide currently undergoing Phase 3 clinical research. Unlike traditional GLP-1 receptor agonists, R3t@trutide activates three metabolic pathways simultaneously:

• GLP-1 Receptor
• GIP Receptor
• Glucagon Receptor

Researchers are investigating its potential effects on:

• Appetite regulation
• Energy expenditure
• Glucose homeostasis
• Fat metabolism
• Body weight regulation
• Cardiometabolic health

Its triple-agonist mechanism has generated significant scientific interest because it combines incretin activity with glucagon receptor activation, a feature that distinguishes it from dual agonists such as tirzepatide.